OBJECTIVE: To determine the use of melatonin and its role in therapy for pediatric delirium (as either prophylaxis or treatment for delirium) in an academic medical center's PICU. METHODS: This retrospective, single-center study reviewed patients between 1 and 18 years of age admitted to the PICU between April 1, 2014, and February 29, 2019. Patients were included if they were admitted for greater than 48 hours and received melatonin for the indication of "delirium." Patients were excluded if melatonin was a home medication. Data collected included baseline characteristics, sedation and antipsychotic usage, assessment scores, and admission overview data. Descriptive statistics were used to report categorical data as percentages. RESULTS: A total of 63 patients were included. Thirty-nine patients (62%) required antipsychotics post-melatonin exposure, with risperidone being the most frequently used agent. The average cumulative antipsychotic exposure pre- and post-melatonin initiation was 2 versus 13 days. The average cumulative exposure to sedating agents, including opioids, benzodiazepines, ketamine, dexmedetomidine, and propofol, pre- and post-melatonin initiation was 13 versus 10 days. The average hospital and PICU lengths of stay were 54 and 39 days, respectively. The initiation of melatonin was also associated with lighter levels of sedation and decreased pain scores. CONCLUSION: Although the initiation of melatonin does not appear to decrease antipsychotic use, the results of this study may suggest a potential prophylactic effect in reducing the days of sedation the patient receives while inpatient. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2021.
OBJECTIVE: To determine the use of melatonin and its role in therapy for pediatric delirium (as either prophylaxis or treatment for delirium) in an academic medical center's PICU. METHODS: This retrospective, single-center study reviewed patients between 1 and 18 years of age admitted to the PICU between April 1, 2014, and February 29, 2019. Patients were included if they were admitted for greater than 48 hours and received melatonin for the indication of "delirium." Patients were excluded if melatonin was a home medication. Data collected included baseline characteristics, sedation and antipsychotic usage, assessment scores, and admission overview data. Descriptive statistics were used to report categorical data as percentages. RESULTS: A total of 63 patients were included. Thirty-nine patients (62%) required antipsychotics post-melatonin exposure, with risperidone being the most frequently used agent. The average cumulative antipsychotic exposure pre- and post-melatonin initiation was 2 versus 13 days. The average cumulative exposure to sedating agents, including opioids, benzodiazepines, ketamine, dexmedetomidine, and propofol, pre- and post-melatonin initiation was 13 versus 10 days. The average hospital and PICU lengths of stay were 54 and 39 days, respectively. The initiation of melatonin was also associated with lighter levels of sedation and decreased pain scores. CONCLUSION: Although the initiation of melatonin does not appear to decrease antipsychotic use, the results of this study may suggest a potential prophylactic effect in reducing the days of sedation the patient receives while inpatient. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2021.
Entities:
Keywords:
antipsychotic; delirium; melatonin; pediatric intensive care unit; prophylaxis; sedation
Authors: Margaret-Ann Carno; Leslie A Hoffman; Richard Henker; Joseph Carcillo; Mark H Sanders Journal: Pediatr Crit Care Med Date: 2004-05 Impact factor: 3.624
Authors: Amanda C Capino; Amber N Thomas; Samantha Baylor; Kaitlin M Hughes; Jamie L Miller; Peter N Johnson Journal: J Pediatr Pharmacol Ther Date: 2020
Authors: John W Devlin; Yoanna Skrobik; Céline Gélinas; Dale M Needham; Arjen J C Slooter; Pratik P Pandharipande; Paula L Watson; Gerald L Weinhouse; Mark E Nunnally; Bram Rochwerg; Michele C Balas; Mark van den Boogaard; Karen J Bosma; Nathaniel E Brummel; Gerald Chanques; Linda Denehy; Xavier Drouot; Gilles L Fraser; Jocelyn E Harris; Aaron M Joffe; Michelle E Kho; John P Kress; Julie A Lanphere; Sharon McKinley; Karin J Neufeld; Margaret A Pisani; Jean-Francois Payen; Brenda T Pun; Kathleen A Puntillo; Richard R Riker; Bryce R H Robinson; Yahya Shehabi; Paul M Szumita; Chris Winkelman; John E Centofanti; Carrie Price; Sina Nikayin; Cheryl J Misak; Pamela D Flood; Ken Kiedrowski; Waleed Alhazzani Journal: Crit Care Med Date: 2018-09 Impact factor: 7.598
Authors: Chani Traube; Gabrielle Silver; Ron W Reeder; Hannah Doyle; Emily Hegel; Heather A Wolfe; Christopher Schneller; Melissa G Chung; Leslie A Dervan; Jane L DiGennaro; Sandra D W Buttram; Sapna R Kudchadkar; Kate Madden; Mary E Hartman; Mary L deAlmeida; Karen Walson; Erwin Ista; Manuel A Baarslag; Rosanne Salonia; John Beca; Debbie Long; Yu Kawai; Ira M Cheifetz; Javier Gelvez; Edward J Truemper; Rebecca L Smith; Megan E Peters; A M Iqbal O'Meara; Sarah Murphy; Abdulmohsen Bokhary; Bruce M Greenwald; Michael J Bell Journal: Crit Care Med Date: 2017-04 Impact factor: 7.598
Authors: Jennifer Foster; Lisa D Burry; Lehana Thabane; Karen Choong; Kusum Menon; Mark Duffett; Alexandra Cheung; Melanie Guenette; Timothy Chimunda; Louise Rose Journal: Syst Rev Date: 2016-11-24
Authors: F Eduardo Martinez; Matthew Anstey; Andrew Ford; Brigit Roberts; Miranda Hardie; Robert Palmer; Lynn Choo; David Hillman; Michael Hensley; Erin Kelty; Kevin Murray; Bhajan Singh; Bradley Wibrow Journal: Trials Date: 2017-01-06 Impact factor: 2.279